Filana Therapeutics, Inc. (FLNA) - Net Assets
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has net assets worth $68.14 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.37 Million) and total liabilities ($40.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Filana Therapeutics, Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $68.14 Million |
| % of Total Assets | 62.88% |
| Annual Growth Rate | -31.1% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.99 |
Filana Therapeutics, Inc. - Net Assets Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. See Filana Therapeutics, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual net assets of Filana Therapeutics, Inc. from 2022 to 2025. For live valuation and market cap data, see market value of Filana Therapeutics, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $74.40 Million | -48.94% |
| 2024-12-31 | $145.70 Million | +5.99% |
| 2023-12-31 | $137.47 Million | -39.58% |
| 2022-12-31 | $227.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Filana Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21253200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.06% |
| Other Components | $570.44 Million | 766.69% |
| Total Equity | $74.40 Million | 100.00% |
Filana Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Filana Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changhong Meiling Co Ltd B
SHE:200521
|
$58.45 Million |
|
ARRAS MINERALS CORP.
F:9RJ
|
$58.47 Million |
|
Hana Must SPAC 2
KQ:208370
|
$58.47 Million |
|
Formosa Prosonic Industries
KLSE:9172
|
$58.48 Million |
|
M2I Corporation
KQ:347890
|
$58.44 Million |
|
Inhwa Precision Co. Ltd
KQ:101930
|
$58.44 Million |
|
Pansari Developers Limited
NSE:PANSARI
|
$58.43 Million |
|
Selic Corp Public Company Limited
BK:SELIC
|
$58.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Filana Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 145,704,000 to 74,403,000, a change of -71,301,000 (-48.9%).
- Net loss of 90,973,000 reduced equity.
- Other factors increased equity by 19,672,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-90.97 Million | -122.27% |
| Other Changes | $19.67 Million | +26.44% |
| Total Change | $- | -48.94% |
Book Value vs Market Value Analysis
This analysis compares Filana Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.21x to 0.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $5.66 | $1.21 | x |
| 2023-12-31 | $3.28 | $1.21 | x |
| 2024-12-31 | $0.03 | $1.21 | x |
| 2025-12-31 | $1.54 | $1.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Filana Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -122.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-122.27%) is below the historical average (-60.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -33.51% | 0.00% | 0.00x | 1.03x | $-99.00 Million |
| 2023 | -70.72% | 0.00% | 0.00x | 1.10x | $-110.96 Million |
| 2024 | -16.71% | 0.00% | 0.00x | 1.08x | $-38.91 Million |
| 2025 | -122.27% | 0.00% | 0.00x | 1.59x | $-98.41 Million |
Industry Comparison
This section compares Filana Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $68.14 Million | -33.51% | 0.59x | $58.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more